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Background: Retrospective analysis of patients with medically
inoperable non-small cell lung cancer treated with continuous high-
dose external beam radiation therapy at the Medical University of
South Carolina.
Methods: We identified 35 patients with non-small cell lung cancer
treated 1998-2002. None were candidates for resection for reasons
including: pulmonary function (n  23), previous cancer (n  9),
other co-morbidities (n 2), and refusal of surgery (n 1). Median
percent predicted forced expiratory volume in 1 second was 41.5%.
Median age was 71 years. Five patients had more than one primary
tumor: three were concurrently treated, two were sequentially
treated. Lesion sizes were3 cm (n 24); 3-5 cm (n 12), and5
cm (n  5). Nodal stage was as follows: N0 (n  33) and N1 (n 
2). Radiation therapy was administered once daily: median dose was
80.5 Gy/35 fx/2.3 Gy/fx. The clinical target volume was tumor plus
nodes1.0 cm. V20 data were available for 12 patients, with a mean
value of 15.7%.
Results: Thirty-four patients completed treatment. Median fol-
low-up was 23.0 months. There were 26 deaths: 19 died from
non-small cell lung (73%) and seven died from co-morbid illness
(27%). Median survival was 24 months (95% CI, 18.0–31.9
months). Four patients were alive with disease, and five were alive
disease-free at 10- and 68-month follow-ups. Of 41 lesions, local
failure occurred in 15 lesions (37%) of which 3 local failure patients
(9%) failed concomitantly in untreated regional lymph nodes. There
were no isolated nodal recurrences. Distant progression: 10 patients
(29%) of which 6 distant progression without local failure. Two
patients who both had prior lobectomies experienced grade 5 tox-
icities.
Conclusion: Continuous high-dose external beam radiation therapy
80.5 Gy administered in 35 fractions was tolerated. Treatment-
related death was rare (6%) and isolated to patients with prior
lobectomies in an extremely high-risk population. Most mortality
was lung cancer-related. The dose of 80.5 Gy in 7 weeks is
supported for patients with single lesions and no prior lobectomy.
Local failure dominates and higher effective doses should be ex-
plored.
Key Words: Radiation oncology, Lung neoplasms, Radiotherapy,
Carcinoma, Non-small cell lung cancer, Retrospective studies,
Dose-response relationship, Radiation.
(J Thorac Oncol. 2006;1: 112–119)
Surgery remains the treatment of choice for early stagenon-small cell lung cancer (NSCLC). The 5-year survival
rate for T1N0 NSCLC approaches 70 to 80% among surgi-
cally treated patients.1,2 However, a substantial number of
patients are medically inoperable because of co-morbid con-
ditions, such as poor pulmonary function, which can lead to
higher operative morbidity and mortality. Sometimes these
patients are treated with definitive radiotherapy as an alter-
native to surgery. Multiple reviews and subgroup analyses
have analyzed treatment of medically inoperable lung cancer
(MILC) with radiotherapy using a variety of different total
dose and fractionation schedules. Retrospective reviews have
estimated 3-year overall survival rates to range from 21 to
55% and 5-year overall survival rates to range from 10 to
32%. Mean total doses approached 65 Gy, and a large
proportion of these patients commonly received elective
nodal irradiation.3–7 In a review of 10 studies, Sibley8 re-
ported a consistent benefit to higher radiotherapy doses in
terms of local control and disease-free survival. Patients
received a median dose of 60 to 66 Gy. Of the patients, 15%
were long-term survivors, and 30% of patients died after local
failure only. Randomized data updated by Ghosh et al. 9
reported a 39% 5-year survival rate among patients treated
with continuous hyperfractionated accelerated radiotherapy
and older than 70 years with stage I lesions. Although this
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compares poorly with the 68% 5-year survival rate for pa-
tients receiving lobectomies alone in that same study, selec-
tion and eligibility for surgery may comprise a subset of
patients with favorable outcomes regardless of treatment.
The current trend is for a reduction of overall treatment
time using hypofractionation schemes with very large frac-
tions given over 1 to 2 weeks. Although this adds conve-
nience and seems tolerable, the convenience must be bal-
anced against risk.10,11 Such risks include the potential injury
to normal tissues as a result of motion of the target or lack of
precision of any beam or fraction that could result in both a
miss and deposition of a damaging dose to normal lung,
bronchus, esophagus, or other normal structure. Short-course
hypofractionated schedules may overcome the accelerated
repopulation of resistant tumor cells that occurs with more
traditional extended fractionation schemes. However, the
classic radiobiological theory of re-oxygenation, re-assort-
ment of cells in the cell cycle, and maintenance of safe
normal tissue effects could favor maintaining a more modest
dose per fraction administered over multiple weeks. A bal-
ance between the trend toward extremely high doses per
fraction schedules and a simple dose escalation of traditional
fractionation schedules seems in order. We have therefore
undertaken a review of a single institution’s experience in
treating patients with medically inoperable NSCLC with
conformal high-dose external radiation therapy (CHERT)
administered daily over 7 weeks to a total dose of 80.5 Gy.
This was a consistent treatment policy based on principles of
conformal three-dimensional radiotherapy as described by
investigators at the University of Michigan.12 We conducted
an analysis of patterns of failure and treatment tolerability
among a group of patients treated using a common high-dose
conformal method.
PATIENTS AND METHODS
We retrospectively reviewed charts of patients with
MILC treated with CHERT at the Medical University of
South Carolina between 1998 and 2002. We sought and
obtained exemption from the institutional review board to
analyze and report this data set. Documentation of informed
consent for treatment was signed by each patient or their legal
representative and placed in the patient’s medical record.
Patients were included in this review if they had a diagnosis
of technically resectable NSCLC that was inoperable because
of medical co-morbidities. Patients with metastatic disease
were excluded from this analysis with the exception of one
patient treated for a solitary brain metastasis before the
discovery of the lung primary tumor. Patients were staged by
applying the criteria from the American Joint Committee on
Cancer Cancer Staging Manual 5th edition. Initial evaluation
and staging included a detailed history and physical evalua-
tion as well as a computed tomographic scan of the chest and
upper abdomen in all patients. Mediastinoscopies were not
performed as these patients were considered to be medically
inoperable. Positron emission tomographic scanning was not
routinely performed in the initial staging as this modality was
not available during the study period. All patients had biopsy-
proven NSCLC. Thirty-five patients who met these criteria
were identified.
The patients were evaluated in a multidisciplinary tho-
racic oncology clinic and tumor conference, which included a
thoracic surgeon, pulmonologist, medical oncologist, radia-
tion oncologist, radiologist, and pathologist. None of these
patients was a candidate for resection based on evaluation by
this board. The patients’ tumors were considered to be tech-
nically resectable but inoperable because of the patients’ poor
pulmonary function and/or co-morbid conditions. There were
no other exclusion criteria. The reasons for medical inoper-
ability are discussed below.
Table 1 shows the patient characteristics. Most of the
patients had compound co-morbidities. Of the patients, 23
were considered to have MILC primarily resulting from poor
TABLE 1. Patient Characteristics
Age (yr)
Median 71
Range 49-93
Gender
Male 23 (66)
Female 12 (34)
Race
White 28 (80)
Black 7 (20)
Lesions per patient
Single 30 (86)
Multiple 5 (14)
T stage
T1 24 (59)
T2 13 (31)
T3 4 (10)
N stage
N0 33 (94)
N1 2 (6)
Stagea
IA 17 (49)
IB 10 (28)
IIA 0 (0)
IIB 7 (20)
III 0 (0)
IV 1 (3)
Tumor size (cm)
3 24 (59)
3-5 12 (29)
5 5 (12)
Tumor location
Upper lobe 25 (61)
Middle or lower lobe 16 (39)
Pulmonary functionb
FEV1 (% predicted)
Median 41.5
Range 14-108
Data are presented as n (%).
aStage of five patients with multiple primaries reflects largest lesion present
bData are unavailable for eight patients
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pulmonary function. Of these 35, 13 (37%) required home
oxygen pretreatment. Pretreatment pulmonary function data
were not available for all patients included in this report. Of
the 23 patients considered to have MILC resulting from poor
pulmonary function, formal testing data were unavailable for
only four patients. Of the available patient data, the median
forced expiratory volume in 1 second (FEV1) was 41% of the
predicted value. Considering all of the patients, data were
unavailable for eight. The median FEV1 was 41.5% of the
predicted value when considering the entire study group.
Unfortunately, precise documentation of performance status
and weight loss was not included in the patients’ medical
records in a systemic way to allow for accurate reporting.
Ten patients had previous cancers. This includes 5
patients with prior thoracic surgery for lung cancer (four of
which were lobectomies and one was a wedge resection).
Another patient had a prior esophageal cancer that had been
treated with esophagectomy. One patient had a previously
resected colon cancer. One patient had a solitary brain me-
tastasis treated with whole brain irradiation prior to the
discovery of the primary tumor. Two other patients were
considered unresectable due to the severity of their conges-
tive heart failure. Only one patient refused surgery but this
patient also had previously resected colon cancer and two
lung lesions in different lobes. One patient had a history of
limited stage small cell lung cancer.
Histological confirmation was obtained in all cases. Of
41 lesions, histologic type: squamous (n  18), “NSCLC”
(n  13), adenocarcinoma (n  10). Tumor size was avail-
able for all the tumors and was measured as the largest
diameter in pre-treatment CT scans. Most patients had N0
disease (33 of 35). Two patients had N1 disease. All of the
patients were considered to have stage I or II disease, except
for the patient who had the solitary brain metastasis. Five
patients had more than one primary tumor. This was deter-
mined based on radiographic imaging, biopsy, and consensus
opinion at the multidisciplinary thoracic tumor board. Of
these five patients, four had multiple T1 and/or T2 lesions but
were otherwise staged as N0. Two of these four patients were
treated with concurrent radiation fields and two were treated
successively. One patient had a combination of T2 and T1
lesions as well as N1 disease. These lesions were treated
concurrently.
The follow-up schedule for these patients was some-
what variable and attending physician dependent. In general,
these patients were seen 3-4 times a year for the first 2-3 years
with a gradual extension to follow-up visits once every 6
months by the five year mark. CT imaging was in general the
preferred imaging modality and obtained at each follow-up
visit other than the initial post-treatment visit when a chest
x-ray was obtained to assess for acute toxicity.
RADIATION TREATMENT
Radiation therapy was delivered once daily with mega-
voltage energy (6-18 MV) external beam radiotherapy using
three-dimensional conformal techniques (Table 2). Treatment
planning computed tomographic scans were obtained during
quiet respiration. No attempt was made to obtain this scan at
any particular phase of respiration. The gross tumor volume
included the tumor plus any lymph node measuring 1.0 cm or
larger. The prescribed dose for 34 of the 35 patients was 80.5
Gy in 35 fractions at 2.3 Gy per fraction. One patient was
prescribed 90.3Gy in 43 fractions at 2.1 Gy per fraction.
These doses were chosen based on the University of Michi-
gan dose-escalation data and were a consistent institutional
treatment policy.12 Less intensive total dose and fractionation
schedules were not used during this time frame. Palliative
dose radiotherapy was used during this review period for
life-threatening airway obstruction or hemoptysis, but those
patients in general had T4 or advanced T3 disease and were
beyond the scope of this review. The gross target volume was
identified on the pulmonary windows of a standard 1990s-era
diagnostic computed tomographic scanner when contouring
lung parenchyma and on mediastinal windows when contour-
ing hilar lymph nodes or mediastinal structures. No effort was
made to treat any non-pathologically enlarged lymph nodes
within the lung hilum or mediastinum (elective nodal irradi-
ation). The clinical target volume was equal to the gross
target volume. The mean planning target volume margin was
1.16 cm (range,1-2 cm depending on the location of the lesion
and information obtained from fluoroscopy). The dose was
prescribed such that the 90 to 95% isodose curve encom-
passed the planning target volume. All treatments were de-
livered using continuous course radiation therapy. No at-
tempts to gate, use intensity modulated radiotherapy, or
accommodate for motion or breath-holding was used during
this study period. The use of fluoroscopy was dependent on
the judgment of the attending physician. There was no insti-
tutional standard for routinely including fluoroscopic data in
the treatment plan.
TABLE 2. Treatment Details
Dose (Gy)
Median 80.5
Range 75.9-90.3
PTV margin (cm)
Mean 1.16
Range 1.0-2.0
Beams (n)
Median 4
Range 2-6
Treatment volume(cm3)
Mean 52.2
Range 3.0-268.8
V20 (%)a
Median 14.0
Range 4-24
Mean lung dose (cGy)b
Median 730.5
Range 229-1377
PTV, planning target volume.
aData were available for 12 patients.
bData were available for 15 patients.
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STATISTICAL ANALYSIS
Radiation therapy charts and hospital records were
reviewed. Survival and patterns of treatment failure were
measured. Local progression was defined as radiographic
evidence of tumor progression at the primary site. Regional
progression was defined as any radiographic or clinical evi-
dence of disease recurrence in regional lymph nodes outside
the original treatment portals. Distant progression was de-
fined as any clinical or radiographic evidence of disease
spread outside the local treatment field or regional lymph
nodes.
These data were analyzed using both SAS statistical
software and GraphPad Prism version 4.03 for Windows
(GraphPad Software, San Diego, CA). The time for survival
or failure was calculated from the starting date of treatment.
Survival and patterns of failure curves were estimated using
the Kaplan-Meier method.13 Proportional hazards regression
analysis was used to evaluate any significant effect of T stage
or tumor size on overall survival.
RESULTS
Of the 35 patients, 34 completed their planned treat-
ment. One patient prescribed to receive 80.5 Gy stopped
treatment at 75.9 Gy because of worsening shortness of
breath. The median primary tumor dose was 80.5 Gy (range,
75.9–90.3 Gy) delivered in 35 fractions of 2.3 Gy per
fraction. The median number of treatment beams used was
four. The mean treatment volume was 52.2 cm3. V20 data
(percent volume of healthy lungs receiving a dose 20 Gy)
were available for 12 patients with a mean value of 15.7%.
Mean total lung dose was available for 12 patients with a
mean value of 844.9 cGy.
Median length of follow-up was 23 months (range,
2-68 months). The extremely short follow-up occurred in
patients with grade 5 toxicities or early death. Among pa-
tients live at the time of this analysis, follow-up ranged from
10 to 68 months. Median survival for the entire cohort was 24
months (95% CI, 18.0–31.9) (Figure 1). As of this analysis,
four patients remain alive with disease and five patients were
alive and free of recurrent disease. Twenty-six deaths oc-
curred: 19 were related to NSCLC, and seven died from
causes attributable to their co-morbid conditions. When re-
analyzing the data by excluding patients with prior life-
threatening malignancies, distant metastasis, prior lung can-
cer resections, or multiple primary tumors, the cohort size
was reduced to 21 patients, but the median survival remains
24 months.
Of the 19 deaths related to NSCLC, two were related to
grade 5 potentially treatment-associated toxicities. The first
patient died 1 month post-treatment with worsening pulmo-
nary function. This patient had undergone a bilobectomy 7
years previously for NSCLC. This patient had a pretreatment
diffusing capacity of the lungs for carbon monoxide (DLCO)
of 23% of the predicted value. The other patient who died had
undergone a prior lobectomy for NSCLC approximately 4
years before receiving CHERT. This death occurred 1 week
post-treatment. The patient had a pretreatment DLCO of 65%
of the predicted value. Three lesions were treated concur-
rently to a dose of 80.5 Gy. The total lung volume treated was
1347 cm3, representing 24% of the total lung volume receiv-
ing greater than 20 Gy. At autopsy, we learned that this
patient had the three treated lesions controlled, but a fourth
tumor was identified. The cause of death at autopsy was
attributed to pulmonary embolism and myocardial infarction,
but it is reasonable to consider the potential that treatment
contributed to these terminal events.
Five patients had multiple lesions treated with CHERT,
bringing the total number of tumors treated to 41 in 35
patients. Local progression occurred in 15 patients (37%). Of
these 15 patients with local failure, three patients also failed
concomitantly in regional lymph nodes outside the original
treatment portals. None of the patients received elective nodal
irradiation. No patients experienced an isolated regional
nodal failure based on follow-up computed tomographic
imaging. The 2- year actuarial local control was 48.5% (95%
CI, 30.0–67.5%). Distant progression occurred in 10 patients
(29%). Of these patients, six had distant progression without
local failure. The 3-year actuarial freedom from distant fail-
ure was 63.3% (95% CI, 44.4–84.0%) Figure 2. Given the
small sample size, no apparent pattern of failure could be
attributed to tumor size or T stage alone (P  0.94 and 0.86,
respectively). Approximately 59% of the lesions were smaller
than 3 cm in size or T1. These tumors had a relatively even
distribution in local versus regional versus distant progres-
sion. Table 3 shows the patterns of failure.
Death from lung cancer occurred in 19 of 26 patient
deaths. We attribute two of these deaths to treatment (5.7% of
the study population). Of the seven patients with deaths
attributable to co-morbid conditions, three patients survived
18 months. The other four patients survived less than 1
year. These patients had poor respiratory function with a
median DLCO 27% of predicted (range, 6–35%) and median
FEV1 45% of predicted (range, 15–59%).
Treatment-related complications are described in Table
4. Beside the attributed treatment-related deaths, the compli-
FIGURE 1. Kaplan-Meier overall survival curve for all 35
patients.
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cations were negligible. One patient was considered to have
grade 3 acute radiation pneumonitis. This patient stopped
treatment at 75.9 Gy of the planned 80.5-Gy total dose and
was followed for 9 months with stable disease and symptoms.
There was no other grade 3 or higher complications. Figures
3 and 4 show representative pre- and post-treatment com-
puted tomographic images.
DISCUSSION
Patients with medically inoperable but technically re-
sectable early-stage lung cancer present a management prob-
lem without a standard of care. Many consider poor lung
function to be a relative contraindication to surgery; however,
there are no evidence-based standards to support that philos-
ophy. Because of this, many patients are not treated and are
expected to die from their co-morbid condition before lung
cancer presents a problem. However, untreated lung cancer
has a dismal prognosis. McGarry et al.14 studied 128 patients
with clinical stage I and IIa NSCLC. Of these patients, 38%
received no specific cancer treatment. Median survival in
untreated patients was 14.2 months; 53% of these patients
died from problems attributed to their cancer. Death from
lung cancer predominated in untreated patients. Of these
patients, 29% were eligible for but refused surgery. There-
fore, caution is needed in applying these results to patients
FIGURE 2. Actuarial curve of failure-free survival.
TABLE 3. Patterns of Failure According to Size and T Stage
Local failure Nodal failure Distant failure
Size (cm)
3 8 1 7
3 7 2 3
T stage
T1 6 1 7
T2 7 2 2
T3 2 0 1
Total 15 3 10
Patterns of failure reported as total failures. Patients with combinations of local,
nodal, and distant failures scored as both. No isolated nodal failures without local failure
occurred.
TABLE 4. Complications
Toxicity Grade 3 Grade 4 Grade 5
Acute radiation pneumonitis 1 0 2
Acute radiation esophagitis 0 0 0
Acute skin toxicity 0 0 0
Acute heart toxicity 0 0 0
Source: National Cancer Institute Common Toxicity Criteria version 2.0
FIGURE 3. Pre-treatment computed tomographic imaging
showing right upper lobe malignancy.
FIGURE 4. Three-year follow-up imaging for the same pa-
tient showing radiographic improvement. The patient was
otherwise without evidence of disease.
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with MILC not resulting from treatment refusal. Patients in
the untreated group who refused therapy would be more
logically expected to be more likely to die from lung cancer
than other causes simply because the inferred burden of
co-morbidities in these patients is less. In the group of
patients included in our study, all but one were not surgical
candidates. Of the 26 deaths, 19 (73%) were attributable to
lung cancer, which bolstering the argument that patients with
MILC die from their cancer and not from co-morbidities;
therefore, non-morbid treatment seems prudent.
Multiple reviews and subgroup analyses have examined
treating MILC with radiotherapy using many different total
dose and fractionation schedules.3,4,5,6,7,9,12,15–17 There is no
established treatment duration, dose, volume, or schedule
with radiotherapy for patients with MILC. Table 5 outlines
the results of several of these studies with the methods used.
One randomized trial comparing continuous hyperfraction-
ated accelerated radiotherapy with surgery using a subgroup
analysis has approached this issue. All of the remaining
studies are reviews of single institutional experiences. Al-
though large fraction hypofractionated studies are becoming
increasingly popular, the follow-up for safety and effect is
quite short.10,11
The use one to eight fractions of external beam therapy
has been examined by several groups.11,18,19 Not only is the
short course of treatment appealing for convenience, these
fractionation schemes also have very high biologically effec-
tive doses (BED), which could increase the cell kill per
fraction within the tumor. The BED is based on the principles
of the linear quadratic equation in which BED  D (1 
d/[/]) and D total dose, d fractional dose, and / 
constant inferred from multifraction experiments in systems
scoring non-clonogenic end points.20 Assuming lung tumor
has an / of 10 and late-responding normal tissues have an
/ of 3, comparative BEDs are shown in Table 6. It is clear
that a steep increase in BED to the tumor is obtained with
hypofractionated techniques. However, the short follow-up of
these various reports leaves wide open the issue of what
effect the high BED to late-responding normal tissues would
have on toxicity. With careful planning, tight margins, atten-
tion to motion, and careful treatment set-up, these toxicities
may prove to be tolerable. At the very highest doses, five
grade 5 toxicities were reported among 70 patients treated
using well-controlled and -described techniques.11 The opti-
mal dose may be more in the range of the moderate /  3
BED fractionation schemes, such as the one we report,
because of toxicity with more aggressive regimens. Well-
controlled prospective trials are needed to address this ques-
tion.
The patients in this study were very unfit for surgery
and clearly had few options other than observation. Several of
these patients pushed the limits of the standard TNM staging
system to consider them as having early-stage lung cancer.
One patient had SCLC treated 2 years before receiving
CHERT. Five other patients had multiple NSCLC lesions.
These patients remained in the treatment group largely based
on the consensus at the interdisciplinary tumor board that
they had multiple primary tumors and not metastatic disease.
If we only excluded the patients with multiple lesions, our
results would have looked worse, probably because the pa-
tients with multiple lesions had a reasonable performance
status, making aggressive treatment seem reasonable,
whereas the rest of the cohort had more a unfavorable
performance status, making surgery impossible and radiation
therapy their only curative option. This is perhaps an indica-
tion that performance status matters more than most things in
terms of patients’ overall survival. Unfortunately, formal
performance status was not clearly reported in the reviewed
medical records. Of these patients with multiple primary
lesions, one died as a result of a grade 5 toxicity, as described
in Results. Another had stable disease 7 months post-treat-
ment. Two others had local progression and regional lymph
node progression within 9 months of treatment. The other
patient considered to have multiple primary lesions also had
N1 disease at the start of treatment. This patient then had a
single brain metastasis 4 months post-treatment that was
treated with whole-brain radiotherapy and stereotactic radio-
surgery. The patient died 4 years later from advanced lung
cancer.
The overall rapidity of regional and distant progression
in the patients treated with multiple primary tumors raises
concerns that these patients had a significant degree of unre-
alized occult disease. Pretreatment positron emission tomo-
graphic scans would have been extremely helpful during
TABLE 5. Radiation Therapy for Patients with Medically Inoperable Non-small Cell Lung Cancer
Author Patients (n) Stage Dose (Gy) Median survival (mo) Local failure (%)
Zhang et al.3 44 T1-2 N0-2 (80%T1-2N0) 55-70 36 27 for those with data
Talton et al.4 77 T1-3 N0 60 17 N/A
Sandler et al.5 77 T1-2 60 20 56
Morita et al.6 149 T1-T2 55-75 (mean 64.7) 27.3 N/A
Sibley et al.7 156 T1-2 50-80 (median 64) 18 42 local only
Ghosh et al. 9 19 T1-2 54 CHART N/A 39% 5yr 27
Dosoretz et al.15 152 T1-3 N0-1 50-70 17 70
Bradley16 56 T1-2 59.9-83.8 (median70) 24 25
Krol et al.17 108 T1-2 60-65 (2.5-3 Gy/fx) N/A 31% 3yr 66
Current study 35 T1-3 N0-1 80.5 (2.3 Gy/fx) 24 43
CHART, continuous hyperfractionated accelerated radiotherapy; N/A, not applicable.
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initial staging. These patients make up three of the 13 patients
reported herein who had regional nodal and/or distant pro-
gression.
Both treatment-associated deaths occurred in patients
with prior lobectomies. Conservatively, future patients with
prior lobectomies may be at higher risk of complications from
this treatment. We attributed these deaths to treatment as a
cautionary note; it is just as likely that multiple simultaneous
nodule treatment or medical events were the cause of one
death. Clearly, these events warrant discussion when obtain-
ing patient consent. However, it is quite clear that even with
treatment, lung cancer predominates in causing mortality
even in this patient set with quite substantial co-morbid
conditions.
A recent report of the RTOG 9311 dose-escalation trial
showed an acceptable rate of acute toxicities but a worrisome
trend toward late lung toxicity. This study had a 15% rate of
late lung toxicity in patients treated to a V20 25% and
radiation therapy doses in excess of 77.4 Gy. Among patients
with a V20 of 25 to 37%, the 15% rate of late lung toxicity
occurred at doses of 70.9 Gy and greater.21 V20 data were
available in 12 patients in our study group, with a mean value
of 15.9%. The treatment techniques and tumor sizes were not
dissimilar from the other patients in our study, but, unfortu-
nately, the formal calculations were not completed for the
others at the time of treatment planning. Our results suggest
that late lung toxicity should be relatively uncommon; in-
deed, it was not noted in follow-up. However, not unlike
other retrospective reviews, this study is not sensitive enough
to adequately assess the occurrence of late toxicity, and the
lack of late toxicity reported herein should be interpreted with
caution.
Local failure predominated in this study and occurred
in 43% of patients. All of the local failures occurred at the site
of the primary tumor based on radiographically proven pro-
gression or biopsy. These local failures are most likely the
result of inadequate dose or inadequate tumor volume cov-
erage. We tried to control for daily set-up error, lung excur-
sion, and tissue margin by using computed tomographic
planning and a 1- to 2-cm planning target volume margin,
which was included within the 90 to 95% isodose curve.
We had few patients with regional nodal failures. No
isolated nodal failures were recorded, which is consistent
with other reports given the limitations of a retrospective
review and the inherently variable follow-up. Bradley et al. 16
recently reported only two regional nodal failures among 33
patients treated to a median isocenter dose of 70 Gy without
the addition of elective nodal irradiation. Krol et al.17 used a
60-Gy split course or 65-Gy continuous treatment course and
reported two of 50 patients having an isolated nodal failure.
Of the 50 patients in that study, 14 had some component of
local failure. Hayman et al.22 reported two of 81 assessable
patients with regional lymph node progression without local
failure. Those data also demonstrated that, using a normal
tissue complication probability model and a measurement of
the normal lung volume to be irradiated, small lung volumes
(Veff  0.18) could be irradiated to a dose of 102.9 Gy and
Veff  0.24 could be irradiated to a dose of 84 Gy. Our
findings that the elimination of elective nodal irradiation does
not seem to affect outcome in any major way and that small
treatment volumes are likely to tolerate much higher doses
than volumes previously used to encompass nodal regions are
consistent with those of other studies. In fact, Jeremic et al.23
suggest that doses of at least 65 Gy are necessary for control
of MILC. Given that larger field sizes result in lower deliv-
erable total doses and the predominance of local failure
among these patients, it is reasonable to propose that elective
nodal irradiation may actually be detrimental in terms of both
morbidity and mortality.
Other strategies and technologies must also be studied
for possible improvements in efficacy. Extracranial stereotac-
tic radioablation, reported as a phase I trial10 and now being
evaluated in a multi-institutional phase II trial, could be one
promising way to treat patients with a short course of high-
dose external beam radiation. For patients able to tolerate an
invasive procedure, radiofrequency ablation could be a prom-
ising local control modality, but this needs to be evaluated in
a rigorous clinical trial setting.24 Cryoablation and radiofre-
quency ablation are more invasive techniques that compete
with short-course radiotherapy and the protracted radiother-
apy we report herein.
CONCLUSION
MILC can be treated with radiotherapy. Most of the
deaths in this study were the result of lung cancer, and most
of the treatment failures occurred locally. Although not com-
pelling, these date are worth further investigation. Local
control was achieved in 63% of tumors. CHERT 80.5 Gy in
35 fractions was well tolerated in a debilitated patient set with
serious co-morbidities and minimal functional reserves. Po-
tentially treatment-associated death was unusual (6%) despite
this very unfit patient set, and was isolated to patients with
prior lobectomies. Most of the mortality in the series was
lung cancer-related. Improved patient selection and tech-
niques to account for tumor motion with continued dose
escalation 80.5 Gy may continue to improve local control.
As a disease-related pattern of failure, local failure
dominated, and higher effective doses should be explored, as
TABLE 6. Hypofractionated Schedules with Biologically Effective Doses
Fx scheme Dose/fx BED /  10 (Gy) BED /  3 (Gy) Follow-up (mo) Local control (%)
Current 2.3/35 99 142 23 63
Three: Timmerman11 20 Gy  3 180 460 12 97.8
Four: Nagata et al.18 12 Gy  4 106 240 16 100
Eight: Onimaru et al.19 7.5 Gy  8 105 210 18 100
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should the competing shorter courses of radiotherapy, radio-
frequency ablation, or cryosurgery. The addition of adjuvant
chemotherapy with traditional agents or biologically targeted
therapies may also be efficacious ways to improve treatment
outcomes, but they may not be practical for patients with poor
performance status and attendant co-morbidities.
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